Treatment of haemophilia patients, both A and B, and patients with other coagulation factor deficiencies is normally based on replacement therapy, this is substitution of the missing clotting factor.
Novo Nordisk is dedicated to furthering research into growth disorders and their treatment. We provide numerous services to help patients undergoing growth hormone treatment to live life to the full.
Novo Nordisk is using its knowledge of protein chemistry, understanding of hormones and disease insight to develop efficient treatments for people with obesity.
UK19DI00394 December 2019